Form 4: Denali Therapeutics COFO Granted Equity Awards

Denali Therapeutics' COFO and Secretary, Alexander O. Schuth, was granted 57,700 Restricted Stock Units and options to purchase 173,100 shares of common stock.

Summary

• Alexander O. Schuth, COFO and Secretary of Denali Therapeutics Inc. (DNLI), was granted equity awards on January 3, 2026.
• The awards include 57,700 Restricted Stock Units (RSUs) and options to purchase 173,100 shares of common stock.
• The RSUs will vest 25% on January 3, 2027, and an additional 25% on each annual anniversary thereafter, contingent on continued service.
• The stock options have an exercise price of $16.27 per share and will vest 25% on January 3, 2027, and 1/48 of the shares each month thereafter, contingent on continued service.
• Following these transactions, Schuth directly owns 300,046 shares (including 141,100 unvested RSUs) and indirectly owns 523,749 shares through The Schuth Family Trust.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is a positive signal for executive retention and alignment of interests, reflecting standard compensation practices without indicating any immediate operational or financial issues.

Positives

• Grant of significant equity awards (RSUs and stock options) to a key executive, aligning management's interests with shareholder value.
• The awards have a long-term vesting schedule, encouraging retention and sustained performance from a senior executive.

Future Outlook

The equity grants are structured with multi-year vesting schedules, indicating a long-term commitment to the company's future performance and executive retention.

Industry Context

Equity grants to key executives are a standard practice in the biotechnology and pharmaceutical industry, particularly for companies like Denali Therapeutics, to incentivize long-term performance and align management interests with shareholder returns in a highly competitive and innovation-driven sector.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules is a common compensation practice for executives in the biotechnology industry, comparable to practices at peer companies such as Biogen, Regeneron, and Amgen, which use similar long-term incentive plans to retain talent and drive innovation.
• The specific vesting schedule (25% after one year, then annually for RSUs; 25% after one year, then monthly for options) is typical for executive equity awards, designed to ensure sustained commitment over several years, aligning with industry benchmarks for executive retention and performance incentives.

Related Party Transactions

• The indirect ownership of 523,749 shares by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee, constitutes a related party holding.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with shareholders, potentially leading to better long-term performance and value creation.
• Employees: The compensation structure for a senior executive may set a precedent or reflect the company's overall approach to executive incentives.

Next Steps

• Continued vesting of RSUs and stock options according to the established schedules on January 3, 2027, and subsequent annual/monthly dates.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of equity compensation to a key executive. While it signals alignment of management interests with shareholders and executive retention, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals rather than this specific insider transaction.

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Alexander O. Schuth, Equity Grant